OBJECTIVES

The study aims to prospectively evaluate the risk scoring algorithm of Chemotherapy induced nausea-vomiting (CINV) in patients undergoing chemotherapy.

METHODS

All patients with Gynecological and Gastrointestinal cancers receiving chemotherapy are recruited after obtaining informed-consent. Patients are followed-up on Day-1 and Day-5 to record any evidences of acute and delayed CINV respectively through phone calls. Prior to every cycle of chemotherapy, the scoring-systems are applied to stratify patients into low and high-risk groups. Logistic-regression modelling is applied to compare the risk for grade 2 or greater CINV between patients considered to be at high and low risk. To assess the external-validity of each system, an area under the receiver-operating characteristic curve-(AUROC) analysis is performed.

RESULTS

: The CINV outcomes data from a total of 104 patients (until March 2019) over 326-cycles of chemotherapy was collected. The incidence of acute and delayed CINV was 42.7% and 76.4% respectively. Major significant risk-factors included younger patient age, platinum/anthracycline-based chemotherapy, low alcohol consumption, previous history of morning sickness and nausea/emetic episodes prior to chemotherapy. Both acute and delayed scoring systems had good predictive accuracy when applied to the external validation sample (acute-AUROC: 0.75; 95% CI: 0.69 to 0.80; delayed-AUROC: 0.71; 95% CI: 0.65 to 0.78). Patients identified by the scoring systems to be at high-risk were 3.8 (p = 0.005) and 6.6 (p = 0.002) times more likely to develop grade-2 or greater acute and delayed-CINV respectively.

CONCLUSIONS

: The present research establishes that the scoring-systems can precisely classify the patients at high-risk for acute and delayed CINV. Further, the data collected until October 2019 will be analyzed and presented at the conference.